Apitope News

Latest Press Releases

Apitope awarded €1.2M IWT Grant to apply its proprietary discovery platform to identify therapies for Graves’ Disease and Uvetitis Patients

January 31, 2013

Diepenbeek, Belgium – 31st January 2013 – Apitope, a drug discovery and development company focused on disease modifying peptide treatments for the underlying cause of autoimmune diseases, announces that it secured a €1.2M grant from the Flemish Agency for Innovation by Science and Technology (IWT) on 21st December 2012, to apply its platform discovery technology…

Details

Apitope completes recruitment into its Clinical Trial of ATX-MS-1467 in Multiple Sclerosis

November 28, 2012

Bristol, UK / Hasselt, Belgium – 28th of November 2012 – Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS). Receipt of the first dose of study…

Details

Apitope appoints Hayley French as Commercial Director

November 1, 2010

Bristol, England / Hasselt, Belgium – 1st November 2010 – Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announces today that Hayley French will join its management team as Commercial Director with immediate effect. Hayley will be responsible for maximising the potential of Apitope’s innovative technology platform. Hayley brings with her…

Details

Apitope grows operations with move to St Brandon’s House, Bristol UK

October 1, 2010

Bristol, England / Hasselt, Belgium – 1st October 2010 – Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announced today that it has relocated its UK subsidiary HQ to larger premises at St Brandon’s House in Bristol, England as a result of significant growth in Apitope’s business and staff. St Brandon’s…

Details

Apitope starts new clinical trial of its investigational Multiple Sclerosis treatment

May 18, 2010

Bristol, UK / Hasselt, Belgium – 18th May 2010 – Apitope, the European Biotech Company developing therapeutic peptides to treat autoimmune and allergic diseases, today announced the start of its second phase 1 clinical trial of ATX-MS-1467, in patients with Multiple Sclerosis (MS). MS is a chronic, inflammatory condition of the nervous system and is…

Details